1. Home
  2. |Insights
  3. |SUSPEND Act Gets Moving

SUSPEND Act Gets Moving

Client Alert | less than 1 min read | 11.13.13

On October 29, the House Oversight Committee passed out of committee the Stop Unworthy Spending, or SUSPEND, Act, legislation that would, effective FY2017, consolidate agency suspension and debarment offices into a single "Board of Suspension and Debarment" at GSA and unify the procurement and non-procurement suspension and debarment regulations, among other changes. The SUSPEND Act contains exceptions to allow offices of major agencies to remain in place in certain specified circumstances and for the SBA to retain its authority to suspend or debar entities for misrepresentation of small business status.


Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights